Brief: Biomerica Reports 208% Increase In Q3 2021 Sales Over Q3 2020
April 15 (Reuters) - Biomerica Inc BMRA.O :
* BIOMERICA REPORTS 208% INCREASE IN Q3 FISCAL 2021 SALES,
OVER Q3
FISCAL 2020
* Q3 SALES $3.62 MILLION
* INFOODS IBS DIAGNOSTIC-GUIDED THERAPY CLINICAL TRIAL
EXPECTING
TOP LINE TRIAL RESULTS BY THIRD CALENDAR QUARTER OF 2021
* NET LOSS FOR FISCAL Q3 2021 WAS $1.84 MILLION COMPARED TO
A NET
LOSS OF $0.86 MILLION FOR SAME PERIOD IN FISCAL 2020
Source text for Eikon: urn:newsml:reuters.com:*:nGNXlKRbD
Further company coverage: BMRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomerica
See all newsDiagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders
Brief: Biomerica May Offer Up To $250 Million Of Common Stock, Preferred Stock, Debt Securities, & Warrants
Brief: Biomerica Lands $1.75 Million CDMO Master Services Agreement For IVD Diagnostic Development
Biomerica's Q3 revenue falls, net loss widens on lower manufacturing sales
Brief: Biomerica Q3 Net Income USD -1.31 Million